Key facts
- This page summarizes James E. Flynn's Form 4 filing for AdaptHealth Corp. (AHCO).
- 5 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 12 Mar 2024, 19:01.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Sale
Sale
Sale
Sale
Sale
No transaction description listed
No transaction description listed
Additional SEC filing notes
Section 16 status
James E. Flynn is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Footnote F1
The price reported in Column 4 represents a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.85 to $10.99, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 1, 4, 5, 6 and 7 of this Form 4
Footnote F2
This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the "Reporting Persons"). Deerfield Mgmt IV, L.P. is the general partner of Deerfield Private Design Fund IV, L.P. ("Fund IV"). Deerfield Mgmt, L.P. is the general partner of Deerfield Partners (collectively with Fund IV, the "Funds"). Deerfield Management Company, L.P. ("Deerfield Management") is the investment manager of the Funds. James E. Flynn is the sole member of the general partner of each of Deerfield Mgmt IV, L.P., Deerfield Mgmt, L.P. and Deerfield Management.
Footnote F3
In accordance with Instruction 4(b)(iv) to Form 4, the entire amount of the Issuer's securities held by the Funds or for the benefit of Deerfield Management is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
Footnote F4
The price reported in Column 4 represents a weighted average price. The shares were sold in multiple transactions at prices ranging from $11.00 to $11.04, inclusive.
Footnote F5
The price reported in Column 4 represents a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.83 to $10.99, inclusive.
Footnote F6
The price reported in Column 4 represents a weighted average price. The shares were sold in multiple transactions at prices ranging from $11.00 to $11.26, inclusive.
Footnote F7
The price reported in Column 4 represents a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.69 to $10.70, inclusive.
Footnote F8
Steven Hochberg, a partner in Deerfield Management, previously served as a director of the Issuer until the expiration of his term as a director upon the consummation of the Issuer's initial business combination. The Class A Common Stock owned by Steven Hochberg and reported herein is held for the benefit, and at the direction, of Deerfield Management.
SEC remarks
Please see Joint Filer Information Statement attached as Exhibit 99 hereto. Jonathan Isler, Attorney-in-Fact: Power of Attorney, which is hereby incorporated by reference to Exhibit 24 to a Form 4 with regard to DA32 Life Science Tech Acquisition Corp. filed with the Securities and Exchange Commission on August 3, 2021 by Deerfield Partners, L.P., Deerfield Mgmt, L.P., Deerfield Management Company, L.P. and James E. Flynn.